Clinical trials: Fallopian Tube Cancer
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00114166
- Testing
- topotecan hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer
This project is a multi-center, prospective, randomized controlled clinical observation the safety and efficacy of hyperthermic intraperitoneal chemotherapy as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- EHNPCTASEOC (NCT03180177)
- Testing
- Hyperthermic Intraperitoneal Chemotherapy, Interval debulking surgery, neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Shu-Zhong Cui
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Ovarian Cancer
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
This study is a randomized, open-label, active-controlled, multicenter phase III clinical trial. It is planned to enroll 300 subjects with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary…
- Trial name
- NCT06990503
- Testing
- SHR-A1811, Chemotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Advanced Solid Tumor, HR+/HER2- Breast Cancer
Study of AVZO-021 in Patients With Advanced Solid Tumors
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
- Trial name
- NCT05867251
- Testing
- AVZO-021, Palbociclib, Fulvestrant
- Where
- 13 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Avenzo Therapeutics, Inc.
Epithelial Ovarian Cancer, Peritoneal Cancer
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
This Phase III single-arm study is to evaluate the efficacy and safety of IMGN853 in Chinese adult patients with platinum-resistant high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers (hereafter referred…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05622890
- Testing
- Mirvetuximab Soravtansine
- Where
- 28 sites in China
- Volunteers
- 35 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Ovarian Cancer, Peritoneal Cancer
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00230542
- Testing
- Carboplatin, Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Dana-Farber Cancer Institute
Peritoneal Cancer, Ovarian Cancer
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT02873962
- Testing
- Bevacizumab, Nivolumab, Rucaparib
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Primary Peritoneal Serous Cancer
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
The purpose of this study is to evaluate how the participant's disease (ovarian, primary peritoneal serous, fallopian tube, or papillary serous endometrial cancer) responds to additional treatment with Avastin (bevacizumab).
- Conditions
- Ovarian Cancer, Primary Peritoneal Serous Cancer, Fallopian Tube Cancer
- Trial name
- NCT00866723
- Testing
- bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Beth Israel Deaconess Medical Center
Ovarian Cancer, Fallopian Tube Cancer
Study of Ramucirumab in Ovarian Cancer
The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT00721162
- Testing
- Ramucirumab
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Fallopian Tube Cancer
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Patients who have this kind of cancer are often treated with several drugs. Carboplatin is one that seems to work for many treatment cycles. Even though it may work against the cancer, the patient can become allergic to it.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01248962
- Testing
- carboplatin
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well pemetrexed disodium and carboplatin work in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01001910
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Albert Einstein College of Medicine
Epithelial Ovarian Cancer
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).
- Trial name
- NCT02900560
- Testing
- CC-486, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Translational Research in Oncology
Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/IIa trial studies the side effects and best dose of a type of specialized immune cell (natural killer cell-like cytotoxic T-lymphocytes (CTLs) (nCTLs) and how well they work when given with a vaccine (alpha-type-1…
- Conditions
- Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage IIA Fallopian Tube Cancer AJCC v8
- Trial name
- NCT03735589
- Testing
- Alpha-type-1 Polarized Dendritic Cells, Autologous Natural Killer Cell-like CTLs
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
This early phase I trial tests the safety and side effects of ZN-c3 in treating patients with triple-negative breast cancer or ovarian cancer that have spread to other parts of the body (metastatic or advanced).
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT05368506
- Testing
- Wee1 Inhibitor ZN-c3
- Sponsor
- OHSU Knight Cancer Institute
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product.
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT05617755
- Testing
- AB-1015
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Arsenal Biosciences, Inc.
Ovarian Cancer, Fallopian Tube Cancer
Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
The purpose of this study is to explore the experiences of Black women who receive care for ovarian cancer at Memorial Sloan Kettering Cancer Center, or "MSK" for short.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02928549
- Testing
- semi-structured interviews
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Benign Gynecological Disease, Uterine Fibroids
Prospective Perioperative Clinical Registry for Women Undergoing Benign Gynecological Surgery
This prospective observational registry aims to systematically collect preoperative, intraoperative, and postoperative clinical data from patients undergoing surgery for benign gynecological conditions.
- Conditions
- Benign Gynecological Disease, Uterine Fibroids, Endometriosis, Adenomyosis
- Trial name
- OPGYNBEN (NCT07772076)
- Testing
- Standard Surgical Procedures for Benign Gynecological Conditions
- Where
- Italy
- Volunteers
- 6,000 people
- Sponsor
- IRCCS San Raffaele
Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II
Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy
The purpose of this research study is to see if it is feasible to receive heated chemotherapy or heated intraperitoneal chemotherapy (HIPEC) inserted directly into the abdomen at the time of a Second Look Reassessment Surgery and…
- Conditions
- Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II, Ovarian Epithelial Cancer Stage III, Stage I Fallopian Tube Cancer
- Trial name
- HIPEC (NCT04415944)
- Testing
- Second look laparoscopy reassessment surgery (SLLRS), HIPEC with Carboplatin, FACT-O Quality of Life Questionnaire
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT06469281
- Testing
- 27T51, Cemiplimab, Bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Regeneron Pharmaceuticals